With great interest, we read the recently published meta-analysis by Yu et al. stating that anisodamine was able to improve microcirculation in patients with septic shock, as supported by lower serum lactate levels and less vasopressor requirements in the treated group [1]. However, the mortality rate in the treated group was lower than that in the usual care group, suggesting that this non-significant finding might be attributable to the limited sample size of the current study [1]. The authors describe the potential beneficial effects of anisodamine in detail, but do not mention the numerous side effects. Anisodamine, a tropane alkaloid extracted from the root of Anisodus tanguticus (Maxim.) Pascher in the family Solanaceae, acts as non-specific muscarinic cholinoceptor antagonist competing with acetylcholine for binding to the muscarinic cholinergic receptor, blocking nerve impulses and physiological functions associated with cholinergic neurotransmission [2]. The autonomic receptors distributed in the cardiac, vascular, and airway smooth muscle are mainly muscarinic cholinoceptors [2]. Thus, the antimuscarinic activity of anisodamine can potentially lead to various physiological effects on the cardiorespiratory system [2] and early experimental and clinical studies have indeed reported that structurally-related tropane alkaloids (such as anisodamine, anisodine, scopolamine, and atropine) have potentially undesirable effects on the particularly the cardiovascular systems [2], such as tachycardia and induction of arrhythmia [2] especially atrial arrhythmia [3]. Anisodamine is also know to increase the heart oxygen consumption and can cause torsade de pointes by increasing the QT interval [4]. Anisodamine induces coronary blood vessel dilation, increasing coronary blood flow, while also possibly inducing simultaneous elevation of the ventricular fibrillation threshold [5].
Acknowledgements
None.
Authors' contributions
PMH, SM, SL, DDB designed the paper. All authors participated in drafting and reviewing. All authors read and approved the final version of the manuscript.
Funding
None.
Availability of data and materials
Not applicable.
Declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare to have no competing interests.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Patrick M. Honore, Email: Patrick.Honore@CHU-Brugmann.be
Sebastien Redant, Email: Sebastien.Redant@CHU-Brugmann.be.
Thierry Preseau, Email: Thierry.Preseau@CHU-Brugmann.be.
Bogdan Vasile Cismas, Email: Bogdanvasile.CISMAS@chu-brugmann.be.
Keitiane Kaefer, Email: keitymed@hotmail.com.
Leonel Barreto Gutierrez, Email: Leonel.BarretoGutierrez@chu-brugmann.be.
Sami Anane, Email: Sami.Anane@CHU-Brugmann.be.
Rachid Attou, Email: Rachid.Attou@CHU-Brugmann.be.
Andrea Gallerani, Email: Andrea.Gallerani@CHU-Brugmann.be.
David De Bels, Email: David.DeBels@CHU-Brugmann.be.
References
- 1.Yu Y, Zhu C, Hong Y, et al. Effectiveness of anisodamine for the treatment of critically ill patients with septic shock: a multicentre randomized controlled trial. Crit Care. 2021;25(1):349. doi: 10.1186/s13054-021-03774-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Chen DT, Lin CS, Gu MN, et al. Effects of penehyclidine hydrochloride and anisodamine on acute kidney injury induced by two-hit rats. Afr J Pharm Pharmacol. 2012;6(26):1949–1957. [Google Scholar]
- 3.Zhu CP, Jiang F, Wang RQ, et al. Comparison of efficacy and safety of hyoscine butylbromide versus anisodamine for acute gastric or intestinal spasm-like pain: a randomized, double-blinded, multicenter Phase III trial. J Dig Dis. 2017;18(8):453–460. doi: 10.1111/1751-2980.12504. [DOI] [PubMed] [Google Scholar]
- 4.Andersson KE, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol. 2011;72(2):186–196. doi: 10.1111/j.1365-2125.2010.03813.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Jianping H, Yaochun L, Hongying L, et al. Effects of anisodamine on coronary blood flow and ventricular fibrillaton threshold in isolated rabbit heart. https://en.cnki.com.cn/Article_en/CJFDTOTAL-MAKE701.013.htm.
- 6.Zhang Z, Zhou J, Shang Y, Wang X, Yin R, Zhu Z, et al. Effectiveness of anisodamine for the treatment of critically ill patients with septic shock (ACIdoSIS study): study protocol for randomized controlled trial. Ann Transl Med. 2015;3(17):246. doi: 10.1186/s12967-015-0607-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779–789. doi: 10.1056/NEJMoa0907118. [DOI] [PubMed] [Google Scholar]